**International Recommendations for Electrocardiographic Interpretation in Athletes**

Sanjay Sharma, MD\*1, Jonathan A. Drezner, MD\*2, Aaron Baggish, MD3, Michael Papadakis, MD1, Mathew G. Wilson, PhD4, Jordan M. Prutkin, MD, MHS5, Andre La Gerche, MD, PhD6, Michael J. Ackerman, MD, PhD7, Mats Borjesson, MD, PhD8, Jack C. Salerno, MD9, Irfan M. Asif, MD10, David S. Owens, MD, MS5, Eugene H. Chung, MD, MS11, Michael S. Emery, MD12, Victor F. Froelicher, MD13, Hein Heidbuchel, MD, PhD14, Carmen Adamuz, MD, PhD4, Chad A. Asplund, MD15, Gordon Cohen, MD16, Kimberly G. Harmon, MD2, Joseph C. Marek, MD17, Silvana Molossi, MD18, Josef Niebauer, MD, PhD19, Hank F. Pelto, MD2, Marco V. Perez, MD20, Nathan R. Riding, PhD4, Tess Saarel, MD21, Christian M. Schmied, MD22, David M. Shipon, MD23, Ricardo Stein, MD, ScD24, Victoria L. Vetter, MD, MPH25, Antonio Pelliccia, MD26, and Domenico Corrado, MD, PhD27

\*joint first author

1. Department of Cardiovascular Sciences, St George’s University of London, UK. 2. Department of Family Medicine, University of Washington, Seattle, US. 3. Division of Cardiology, Massachusettes General Hospital, US. 4. Department of Sports Medicine, ASPETAR, Qatar Orthopaedic and Sports Medicine Hospital, Qatar. 5. Division of Cardiology, University of Washington, Seattle, US. 6. Baker IDI Heart and Diabetes Institute, Australia. 7. Department of Cardiovascular Diseases, Pediatric and Adolescent Medicine, and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, US. 8. Department of Neuroscience and Physiology, Sahlgrenska University Hospital/Ostra Sahlgrenska Academy, Goteborg, Sweden. 9. Department of Pediatrics, University of Washington, Seattle, US. 10. Department of Family Medicine, University of South Carolina, Greenville, US. 11. Division of Cardiology, University of North Carolina School of Medicine, US. 12. Center of Cardiovascular Care in Athletics, Indiana University School of Medicine, US. 13. Department of Medicine, Stanford University, US. 14. Hasselt University, Belgium. 15. Georgia Southern University, US. 16. Division of Pediatric Cardiothoracic Surgery, University of California San Francisco School of Medicine, US. 17. Advocate Heart Institute, Illinois, US. 18. Division of Pediatric Cardiology, Baylor College of Medicine, US. 19. University Institute of Sports Medicine, Paracelsus Medical University, Austria. 20. Center for Inherited Cardiovascular Disease, Stanford University, US. 21. Pediatric Cardiology, Cleveland Clinic, US. 22. University of Herzzentrum, Zurich, Switzerland. 23. Heart Center of Philadelphia, Jefferson University Hospitals, US. 24. Department of Cardiology, Hospital de Clinicas de Porte Allegre, Brazil. 25. The Children’s Hospital of Philadelphia, US. 26. Institute of Sports Medicine and Science, Rome, Italy. 27. Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Italy.

Author for correspondence:

Professor Sanjay Sharma

St George’s University of London.

Cranmer Terrace. London. UK

sasharma@sgul.ac.uk

Word Count 6,057

**ABSTRACT**

Sudden cardiac death (SCD) is the leading cause of mortality in athletes during sport. A variety of mostly hereditary, structural or electrical cardiac disorders are associated with SCD in young athletes, the majority of which can be identified or suggested by abnormalities on a resting 12-lead electrocardiogram (ECG). Whether used for diagnostic or screening purposes, physicians responsible for the cardiovascular care of athletes should be knowledgeable and competent in ECG interpretation in athletes. However, in most countries a shortage of physician expertise limits wider application of the ECG in the care of the athlete. A critical need exists for physician education in modern ECG interpretation that distinguishes normal physiological adaptations in athletes from distinctly abnormal findings suggestive of underlying pathology. Since the original 2010 European Society of Cardiology recommendations for ECG interpretation in athletes, ECG standards have evolved quickly over the last decade; pushed by a growing body of scientific data that both tests proposed criteria sets and establishes new evidence to guide refinements. On February 26-27, 2015, an international group of experts in sports cardiology, inherited cardiac disease, and sports medicine convened in Seattle, Washington, to update contemporary standards for ECG interpretation in athletes. The objective of the meeting was to define and revise ECG interpretation standards based on new and emerging research and to develop a clear guide to the proper evaluation of ECG abnormalities in athletes. This statement represents an international consensus for ECG interpretation in athletes and provides expert opinion-based recommendations linking specific ECG abnormalities and the secondary evaluation for conditions associated with SCD.

**INTRODUCTION**

Cardiovascular-related sudden death is the leading cause of mortality in athletes during sport and exercise.1-3 The majority of disorders associated with an increased risk of sudden cardiac death (SCD) are suggested or identified by abnormalities on a resting 12-lead ECG. Whether used for the evaluation of cardiovascular-related symptoms, a family history of inheritable cardiac disease or premature SCD, or for screening of asymptomatic athletes, ECG interpretation is an essential skill for all physicians involved in the cardiovascular care of athletes.

**The 2015 Summit on ECG Interpretation in Athletes**

Over the last decade, ECG interpretation standards have undergone several modifications to improve the accuracy of detecting potentially life threatening cardiac conditions in young athletes while also limiting false positive results.4-15 In February 2015, an international group of experts convened in Seattle, Washington, to update contemporary recommendations for ECG interpretation in asymptomatic athletes aged 12-35 years. The goals of the summit meeting were to: 1) update ECG interpretation standards based on new and emerging research; and 2) develop a clear guide to the appropriate evaluation of ECG abnormalities for conditions associated with SCD in athletes. In the presence of cardiac symptoms or a family history of inherited cardiovascular disease or premature SCD, a normal ECG should not preclude further assessment.

This document provides the most updated evidence-based recommendations developed with thoughtful attention to balance sensitivity and specificity, while maintaining a clear and practical checklist of findings to guide ECG interpretation for physicians and the appropriate evaluation of ECG abnormalities. A summary of the consensus recommendations is presented in Figure 1, Table 1, and Table 2.

**Limitations**

While ECG increases the ability to detect underlying cardiovascular conditions associated with SCD, ECG as a diagnostic tool has limitations in both sensitivity and specificity. Specifically, ECG is unable to detect anomalous coronary arteries, premature coronary atherosclerosis and aortopathies. In some instances patients with cardiomyopathies, particularly arrhythmogenic right ventricular cardiomyopathy (ARVC), may also reveal a normal ECG. Thus, an ECG will not detect all conditions predisposing to SCD. Furthermore, inter-observer variability among physicians remains a major concern,16, 17,18 despite studies demonstrating that using standardized criteria improves interpretation accuracy.19, 20

**NORMAL ECG FINDINGS IN ATHLETES**

**Physiological Cardiac Adaptations to Regular Exercise**

Regular and long-term participation in intensive exercise (minimum of 4 hours per week) is associated with unique electrical manifestations that reflect enlarged cardiac chamber size and increased vagal tone. These ECG findings in athletes are considered normal, physiological adaptations to regular exercise and do not require further evaluation (Figure 1; Table 1).

**Left and Right Ventricular Hypertrophy**

The presence of isolated QRS voltage criterion for LVH (Figure 2) does not correlate with pathology in athletes and is present in isolation (without other associated ECG abnormalities) in less than 2% of patients with HCM.21-27 Conversely, pathological LVH is commonly associated with additional ECG features such as TWI in the inferior and lateral leads, ST segment depression, and pathological Q waves.28, 29 Therefore, the isolated presence of high QRS voltages fulfilling voltage criterion for LVH in the absence of other ECG or clinical markers suggestive of pathology are considered part of normal and training-related ECG changes in athletes and does not require further evaluation.

Voltage criterion for RVH is also common in athletes with up to 13% of athletes fulfilling the Sokolow-Lyon index.30, 31 QRS voltages for RVH, when present in isolation, do not correlate with underlying pathology in athletes.31 Similar to voltage criteria for LVH, isolated QRS voltage for RVH is part of the normal spectrum of ECG findings in athletes and does not require further evaluation.

**Early Repolarization**

Early repolarization is defined as elevation of the QRS-ST junction (J-point) by ≥ 0.1 mV often associated with a late QRS slurring or notching (J wave) affecting the inferior and/or lateral leads.32-34 Early repolarization is common in healthy populations (2-44%) and is more prevalent in athletes, young individuals, males, and black ethnicity.32, 35-39 Early repolarization consisting of J-point elevation with concave ST segment elevation and a peaked T wave I (Figure 2) is present in up to 45% of Caucasian athletes and 63-91% of black athletes of African-Caribbean descent (hereto referred to as “black” athletes).22, 30

Some studies on survivors of cardiac arrest and patients with primary ventricular fibrillation (VF) have suggested an association between early repolarization and the risk of VF.33, 40 Although further studies are warranted to fully elucidate the mechanisms and prognostic implications of early repolarization in competitive athletes, to date there are no data to support an association between inferior early repolarization and SCD in athletes. Based on current evidence, all patterns of early repolarization, when present in isolation and without clinical markers of pathology, should be considered benign variants in athletes.41

**Repolarization Findings in Black Athletes**

Ethnicity is a major determinant of cardiac adaptation to exercise with more than two-thirds of black athletes exhibiting repolarization changes.29, 30, 42, 43 Black athletes also commonly demonstrate a repolarization variant consisting of J-point elevation and convex ST segment elevation in the anterior leads (V1-V4) followed by TWI (Figure 3 and Figure 4 B and C) which is regarded as a normal variant and should not result in further investigation, in the absence of other clinical or ECG features of cardiomyopathy.30, 42-44

**Considerations in Athletes Age 12-16 Years: the “Juvenile” ECG Pattern**

TWI confined to the anterior precordial leads may be considered a normal age related pattern in adolescent athletes up to the age of 16 years old. The term “juvenile” ECG pattern is used to denote TWI or a biphasic T wave beyond lead V2 in adolescents who have not reached physical maturity and is present in 10-15% of white, adolescent athletes aged 12 years old but only in 2.5% of white athletes aged 14-15 years (Figure 4A).22, 45, 46 Anterior TWI that extends beyond lead V2 is rare (0.1%) in white athletes aged ≥ 16 years or younger athletes who have completed puberty.22, 45 Based on current evidence, TWI in the anterior leads (V1-V3) in adolescent athletes < 16 years of age should not prompt further evaluation in the absence of symptoms, signs or a family history of cardiac disease.

**Physiological Arrhythmias in Athletes**

Common consequences of increased vagal tone include sinus bradycardia and sinus arrhythmia.22, 47-49 Other, less common markers of increased vagal tone are junctional or ectopic atrial rhythms, first degree atrioventricular (AV) block, and Mobitz type I second degree AV block (Wenckebach phenomenon).22, 47, 50 In the absence of symptoms, heart rates ≥ 30 bpm are considered normal in highly trained athletes. Sinus rhythm should resume and bradycardia should resolve with the onset of physical activity.

**BORDERLINE ECG FINDINGS IN ATHLETES**

Recent data suggests that some ECG findings previously categorized as abnormal may represent normal variants or the result of physiological cardiac remodeling in athletes and do not usually represent pathological cardiac disease. These ECG findings have been categorized as ‘borderline’ findings in athletes (Figure 1; Table 1).

**Axis Deviation and Voltage Criteria for Atrial Enlargement**

Axis deviation and voltage criteria for atrial enlargement account for > 40% of abnormal ECG patterns in athletes but do not correlate with cardiac pathology.51 In a large study of 2,533 athletes aged 14-35 years old and 9,997 controls of similar age, echocardiographic evaluation of the 579 athletes and controls with isolated axis deviation or voltage criteria for atrial enlargement failed to identify any major structural or functional abnormalities.51

**Complete Right Bundle Branch Block**

Although incomplete RBBB is common in young athletes, the significance of complete RBBB is less certain. Complete RBBB is detected in approximately 1% of the general population and large datasets in young adult athletes reveal a prevalence of 0.5-2.5%.12, 52-54 In a study of 510 U.S. collegiate athletes, RBBB was reported in 2.5% and compared to athletes with normal QRS complexes or incomplete RBBB, athletes with complete RBBB exhibited larger right ventricular dimensions and a lower right ventricular ejection fraction but preserved fractional area change. 55 None of the athletes with complete RBBB or incomplete RBBB was found to have pathological structural cardiac disease. These patterns among trained athletes could represent a spectrum of structural and physiological cardiac remodeling characterized by RV dilation with resultant QRS prolongation and a relative reduction in the RV systolic function at rest.55

Based on the aforementioned considerations, LAD, LAE, RAD, RAE and complete RBBB are considered borderline variants in athletes. The presence of any one of these findings in isolation or with other recognized physiological electrical patterns of athletic training does not warrant further assessment in asymptomatic athletes without a family history of premature cardiac disease or SCD. Conversely, the presence of more than one of these borderline findings places the athlete in the abnormal category warranting additional investigation.

**ABNORMAL ECG FINDINGS IN ATHLETES**

The abnormal findings defined in this section are not recognized features of athletic training and always require further assessment to exclude the presence of intrinsic cardiac disease (Figure 1; Table 1; Table 2). Temporary restriction from athletic activity should be considered for athletes with abnormal ECGs of uncertain clinical significance until secondary investigations are completed.

**Abnormal T Wave Inversion**

TWI ≥ 1 mm in depth in two or more contiguous leads (excluding leads aVR, III, and V1) in an anterior, lateral, inferolateral, or inferior territory is abnormal and should prompt further evaluation for underlying structural heart disease (Table 1; Table 2). Normal exceptions include TWI confined to leads V1-V4 in black athletes when preceded by J point and/or ST segment elevation, and TWI in leads V1-V3 in athletes aged < 16 years.

Clinical Considerations

The relationship between abnormal TWI and several forms of structural heart disease is well documented.56 T wave inversion in the inferior or lateral leads is common in HCM.56-59 Whereas T wave inversion in the right precordial leads (V1-V3) or beyond in the absence of a complete RBBB is common in ARVC (Figure 4 D).60, 61

There are no data relating to the significance of flat or biphasic T waves in athletes but similar to TWI, this panel would recommend further evaluation of biphasic T waves where the negative portion is ≥ 1 mm in depth in ≥ 2 leads.

Evaluation

*Lateral or Inferolateral TWI*

There is mounting evidence that TWI in the lateral or inferolateral leads are associated with the presence of quiescent cardiomyopathy in a considerable proportion of athletes.30, 62-64 Recommendations for the evaluation of abnormal TWI and other clinical considerations are presented in Table 2.

TWI affecting the lateral leads (V5-V6, I and aVL) (Figure 4 E) should prompt a comprehensive investigation to exclude cardiomyopathy. If echocardiography is not diagnostic, cardiac MRI with gadolinium should be utilized. Cardiac MRI provides superior assessment of myocardial hypertrophy, especially the left ventricular apex and the lateral free wall and may also demonstrate late gadolinium enhancement (LGE), a non-specific marker suggesting myocardial fibrosis. If cardiac MRI is not available, echocardiography with contrast should be considered. Exercise ECG testing and Holter monitoring also should be considered in the evaluation of lateral or inferolateral TWI, especially for ‘grey zone’ hypertrophy (maximal LV wall thickness 13-16 mm) without LGE, where the diagnosis of HCM remains uncertain. In such cases, the presence of ventricular tachycardia during exercise or Holter may support HCM and is also useful in risk stratification.65

For athletes with lateral or inferolateral TWI, regular follow-up with serial cardiac imaging is necessary even when the initial evaluation is normal, in order to monitor for the development of a cardiomyopathy phenotype.62, 63

*Anterior TWI*

Anterior TWI is a normal variant in asymptomatic adolescent athletes age < 16 years, in black athletes when preceded by J-point elevation and convex ST segment elevation, and in some endurance athletes.66, 67 However, anterior TWI in leads V1-V2/V3 also is a recognized pattern in patients with ARVC and rarely HCM.

There are discrepancies among existing guidelines relating to the extent of anterior TWI inversion before considering further investigations.5, 6, 14, 29 A large study of over 14,000 white adults aged 16-35 years old, including over 2,500 athletes showed that anterior TWI had a prevalence of 2.3%.68 Anterior TWI was more common in females and athletes and was confined to leads V1-V2 in almost all individuals, and only exceeded beyond V2 in 1% of females and 0.2% of males.68 None of the individuals with anterior TWI were diagnosed with a cardiomyopathy following comprehensive investigation indicating that this particular ECG pattern is non-specific in low risk populations. Based on this report, it is justifiable to only investigate non-black athletes with anterior TWI beyond V2 in the absence of other clinical or electrical features of ARVC.

Specific information about the J-point and preceding ST segment may help differentiate between physiological adaptation and cardiomyopathy in athletes with anterior TWI affecting leads V3 and/or V4. A recent study comparing anterior TWI in a series of black and white healthy athletes, and patients with HCM and ARVC, showed that in athletes with anterior TWI, the combination of J-point elevation ≥ 1 mm and TWI confined to leads V1-V4 excluded either cardiomyopathy with 100% negative predictive value, regardless of ethnicity.66 Conversely, anterior TWI associated with minimal or absent J-point elevation (< 1 mm) could reflect a cardiomyopathy.66 These data require duplication in larger studies but may prove useful in the assessment of a small proportion of white endurance athletes who exhibit anterior TWI and in athletes of black/mixed ethnicity.69

In most non-black athletes age ≥ 16 years, anterior TWI beyond lead V2 should prompt further evaluation given the potential overlap with ARVC. In these athletes, concurrent findings of J-point elevation, ST segment elevation, or biphasic T waves more likely represents athlete’s heart, while the absence of J-point elevation or a coexistent depressed ST segment is more concerning for ARVC (Figure 5).66 Other ECG findings suggestive of ARVC include low limb lead voltages, prolonged S wave upstroke, ventricular ectopy with LBBB morphology, and epsilon waves.61 A combination of tests is needed to diagnose ARVC including echocardiography, cardiac MRI, Holter monitoring, exercise ECG test, and signal averaged ECG.

*Inferior TWI*

The significance of TWI confined to the inferior leads is unknown. However, this finding cannot be attributed to physiological remodeling and thus warrants further investigation with, at minimum, an echocardiogram. Cardiac MRI should be considered based on the echocardiographic findings or clinical suspicion.

**ST Segment Depression**

While ST segment depression is common among patients with cardiomyopathy, it is not a feature of athletic training.28, 59, 70, 71 ST segment depression (relative to the isoelectric PR segment) in excess of 0.05 mV (0.5 mm) in two or more leads should be considered an abnormal finding requiring definitive evaluation for underlying structural heart disease.

Evaluation

Echocardiography is the minimum evaluation for athletes with ST segment depression to investigate for underlying cardiomyopathy. Cardiac MRI should be considered based on the echocardiographic findings or clinical suspicion.

**Pathological Q Waves**

Several pathological disorders including HCM, ARVC, infiltrative myocardial diseases, accessory pathways and transmural myocardial infarction can lead to the development of exaggerated (deep or wide) Q waves or unexpected Q waves in atypical leads.28, 56 Pathological Q waves also may be a result of lead misplacement. In particular, a pseudo-septal infarct pattern with pathological Q waves in leads V1-V2 is commonly due to high lead placement relative to cardiac position.72

Pathological Q waves have been reported in approximately 1-2% of all athletes, and may be higher in males and black athletes.29, 73 For asymptomatic athletes, pathological Q waves were previously defined as > 3 mm in depth or > 40 ms in duration in two or more leads (except III and aVR).6, 10 In practice, however, this criterion is a common source of false positive ECG results as trained athletes with physiological LVH and thin adolescent athletes may have increased precordial voltages and deep lateral or inferior Q waves.

The use of a Q/R ratio overcomes some of these issues by normalizing Q wave depth to the degree of proceeding R wave voltage. Case control analyses of athletes and HCM patients suggest that this will decrease the false positive rate without compromising sensitivity for the detection of cardiomyopathy.29, 74 Thus, this consensus panel has modified the definition for pathological Q waves in athletes as a Q/R ratio ≥ 0.25 or ≥ 40 ms in duration in two or more contiguous leads (except III and aVR).

Evaluation

An ECG with abnormal Q waves should be carefully examined for the possibility of an accessory pathway. If the pathological Q waves are isolated to leads V1-V2, the ECG should be repeated, including re-placing the ECG leads to ensure proper positioning. Persistence of pathological Q waves in two or more contiguous leads warrants further investigation with echocardiography to exclude cardiomyopathy. If the echocardiogram is normal and there are no other concerning clinical findings or ECG abnormalities, no additional testing is generally necessary. However, if there is a high index of clinical suspicion, additional evaluation with cardiac MRI should be considered. In athletes age ≥ 30 years with suspicion of prior myocardial infarction or risk factors for CAD, stress testing may be warranted.

**Complete Left Bundle Branch Block**

LBBB is found in less than 1 in 1,000 athletes but is common in patients with cardiomyopathy and ischaemic heart disease.9, 28, 59, 75, 76 Thus, complete LBBB always should be considered an abnormal finding and requires a comprehensive evaluation to rule out a pathological cardiac disorder.

Evaluation

Athletes with complete LBBB require a thorough investigation for myocardial disease including echocardiography and a cardiac MRI with perfusion study.

**Profound Nonspecific Intra-ventricular Conduction Delay**

Epidemiological studies of nonspecific intra-ventricular conduction delay (IVCD) in the general population have shown an increased risk of cardiovascular death and have been documented among patients with cardiomyopathy.77, 78 The significance of nonspecific IVCD with normal QRS morphology in healthy, asymptomatic athletes is uncertain.79 The physiology underlying IVCD in athletes remains incompletely understood but likely includes some combination of neurally mediated conduction fiber slowing and increased myocardial mass. In patients with LVH, left ventricular mass seems to be closely related to QRS duration.80

While the exact cutoff to trigger more investigation in athletes with a nonspecific IVCD remains unclear, this panel recommends that marked nonspecific IVCD ≥ 140 ms in athletes, regardless of QRS morphology, is abnormal and should prompt further evaluation.

Evaluation

In asymptomatic athletes with profound nonspecific IVCD, an echocardiogram is recommended to evaluate for myocardial disease. Other testing may be indicated depending on echocardiographic findings or clinical suspicion.

**Ventricular Pre-Excitation**

Ventricular pre-excitation occurs when an accessory pathway bypasses the AV node resulting in abnormal conduction to the ventricle (pre-excitation) with shortening of the PR interval and widening of the QRS. This is evident on the ECG as the Wolf-Parkinson-White (WPW) pattern defined as a PR interval < 120 ms, the presence of a delta wave (slurring of the initial QRS), and a QRS duration > 120 ms.81 The WPW pattern occurs in up to 1 in 250 athletes.9, 12, 52, 82 The presence of an accessory pathway can predispose an athlete to sudden death because rapid conduction of atrial fibrillation across the accessory pathway can result in VF.

Evaluation

A short PR interval in isolation without a widened QRS or delta wave in an asymptomatic athlete should not be considered for further assessment. The WPW pattern warrants further assessment of the refractory period of the accessory pathway. Non-invasive risk stratification begins with an exercise stress test, where abrupt, complete loss of pre-excitation at higher heart rates suggests a low risk accessory pathway.83, 84 An echocardiogram also should be considered due to the association of WPW with Ebstein’s anomaly and cardiomyopathy. Intermittent pre-excitation during sinus rhythm on a resting ECG is also consistent with a low risk pathway and may obviate the need for an exercise test.85 If non-invasive testing cannot confirm a low risk pathway or is inconclusive, an electrophysiological study should be considered to determine the shortest pre-excited RR interval during atrial fibrillation.83 If the shortest pre-excited RR interval is ≤ 250 ms (240 bpm), then the accessory pathway is deemed high risk and transcatheter ablation is recommended.83, 86

**Prolonged QT Interval**

Congenital LQTS is a potentially lethal, genetically mediated ventricular arrhythmia syndrome with the hallmark electrocardiographic feature of QT prolongation. LQTS is estimated to affect 1 in 2,000 individuals, and this may be underestimated given the subpopulation of so-called “normal QT interval” or “concealed” LQTS.87 Autopsy negative sudden unexplained death represents 25-40% of sudden unexpected deaths in persons under age 40 years.3, 88-90In such cases, cardiac ion channelopathies have been implicated by post-mortem genetic testing as the probable cause in up to 25-40% of cases.91-94

Calculating the QTc

Accurate measurement and manual confirmation of the computer derived QT interval corrected for heart rate (QTc) is critical as the accuracy of computer generated QTc values is about 90-95%. Studies have suggested the ability of cardiologists to accurately measure the QTc is suboptimal.95However, accurate assessment of the QTc can be achieved by adhering to the following six principles:96

1. Use Bazett’s heart rate correction formula (QTc = QT/√RR; note the RR interval is measured in seconds) as population-based QTc distributions most frequently use Bazett-derived QTc values.97
2. Bazett’s formula underestimates the QTc at heart rates < 50 bpm, and overestimates the QTc at heart rates > 90 bpm. Accordingly, for a heart rate < 50 bpm, a repeat ECG after mild aerobic activity is recommended to achieve a heart rate closer to 60 bpm. For heart rates > 90 bpm, a repeat ECG after additional resting time may help achieve a lower heart rate.
3. If sinus arrhythmia is present with beat to beat variation in heart rate, an average QT interval and average RR interval should be used.
4. Leads II and V5 usually provide the best delineation of the T wave.
5. Low amplitude U waves, which are common in the anterior precordial leads, should not be included in the QT calculation. The “Teach-the-Tangent” or “Avoid-the-Tail” method to delineate the end of the T wave should be followed (Figure 6).96
6. The morphology of the T wave, not just the length of the QT interval, also can suggest the presence of LQTS.98 For instance, a notched T wave in the lateral precordial leads where the amplitude of the second portion of the T wave following the notch is greater than the first portion of the T wave may represent LQT-2 even in the absence of overt QT prolongation.

The easiest and most efficient way to confirm the computer-derived QTc is to examine lead II and/or V5 and determine if the manually measured QT interval matches the computer’s QT measurement. If there is concordance within about 10 ms, one can trust that the computer can derive accurately an average RR interval and complete the Bazett’s calculation. If, however, the manually measured QT interval is > 10 ms different than the computer’s QT measurement, an average RR interval should be determined and the QTc recalculated using the Bazett’s formula.

# QTc Cutoffs

Given the overlap between QTc distributions in population-derived cohorts of healthy individuals compared to patients with genetically confirmed LQTS, the QTc cutoff value compelling further evaluation must be chosen carefully to balance the frequency of abnormal results and the positive predictive value for LQTS.

Recent consensus statements on ECG interpretation in athletes have recommended that male athletes with a QTc > 470 ms and female athletes with a QTc > 480 ms undergo further evaluation for LQTS to better balance false positive and false negative findings.6, 10 These cutoff values are around the 99th percentile and consistent with thresholds defined by the American Heart Association and American College of Cardiology.99 This consensus group also recommends QTc values of > 470 ms in males and > 480 ms in females to define the threshold of QT prolongation that warrants further assessment in asymptomatic athletes.

*Short QT Interval*

The precise cutoff and clinical significance of a short QT interval in athletes is unknown. Data from over 18,000 asymptomatic young British individuals found that the prevalence of a QTc < 320 ms is 0.1%; suggesting an abnormal cutoff value of < 320 ms is pragmatic.100 However, over a mean follow up period of 5.3 years, none of the individuals with a short QT < 320 ms experienced any adverse events, syncope, or sudden death.100 Based on the rarity of this finding and absence of data to suggest long-term morbidity in asymptomatic athletes, this panel recommends that a short QT interval only be investigated in the context of concerning clinical markers.

# Evaluation

It is critical that an athlete with a single prolonged QTc reading not be obligated a diagnosis of LQTS, but rather that these cutoff values trigger the need for additional evaluation. The importance of additional evaluation but not a premature diagnosis of LQTS was demonstrated in a study of 2,000 elite athletes in which 7 (0.4%) had a prolonged QTc (range 460-570 ms).101 A QTc of < 500 ms in the absence of symptoms or familial disease was unlikely to represent LQTS. In contrast, a QTc ≥ 500 ms was highly suggestive of LQTS as all three athletes with a QTc value of > 500 ms exhibited one of paradoxical prolongation of the QTc during exercise, a confirmatory genetic mutation, or prolonged QTc in a first-degree relative.101

A personal history of syncope or seizures and a family history of exertional syncope, “epilepsy”, postpartum-timed syncope/seizure, unexplained motor vehicle accidents, unexplained drowning, and premature, unexplained sudden death < 50 years of age should be reviewed. If the personal/family history is positive, the athlete should be referred to an electrophysiologist for further evaluation. If the personal/family history is negative, a repeat ECG should be obtained (ideally on a different day). If the follow-up ECG is below the QTc cutoff values, then no additional evaluation is needed and the athlete should be reassured.

If the repeat ECG still exceeds the QTc cutoff values, then a screening ECG of the athlete’s first degree relatives (parents and siblings) should be considered and the athlete should be referred to an electrophysiologist for the possibility of newly discovered LQTS. Reversible, extrinsic factors, such as electrolyte abnormalities (hypokalemia) or the presence of QT prolonging medications, must also be evaluated. If an athlete’s ECG shows a QTc > 500 ms and no reversible causes are identified, then the athlete should be referred immediately to an electrophysiologist as the probability of LQTS and future adverse events has increased.102 The Schwartz-Moss scoring system, electrocardiographic features, stress ECG, provocative testing and genetic testing may be needed to clarify the diagnosisand should be performed and interpreted by a cardiologist familiar with the disease.103-106

**Brugada Type 1 Pattern**

Brugada syndrome (BrS) is an inherited primary electrical disease which predisposes to ventricular tachyarrhythmias and sudden death during states of enhanced vagal tone. It is characterized by the distinctive Brugada ECG pattern which consists of a coved rSr’ pattern, ST-segment elevation ≥ 2 mm, and inversion of the terminal portion of the T wave in leads V1, V2, and V3 (Figure 4F). Although three types were described, only the type 1 Brugada pattern is now considered diagnostic.107-109

The coved ST segment elevation in type 1 Brugada pattern results in a broad r’ and should be distinguishable from the upsloping ST segment elevation of early repolarization in an athlete. In this regard, the “Corrado index” measures the ST elevation at the start of the ST segment/J-point (STJ) and 80 ms after the start of the ST segment (ST80).110 In type 1 Brugada pattern the downsloping ST segment will have a STJ/ST80 ratio > 1, while the initial upsloping of the ST segment found in early repolarization patterns in an athlete will produce an STJ/ST80 ratio < 1 (Figure 7).

Evaluation

The type 1 Brugada ECG pattern should be investigated regardless of symptoms. If the pattern is unclear, confirm correct lead placement, repeat the ECG if necessary, and perform a high precordial lead ECG with V1 and V2 placed in the 2nd or 3rd intercostal space. If the type 1 pattern is seen on a high precordial lead ECG, then referral to an electrophysiologist is indicated. Consideration should be given to potential accentuating factors for a Brugada-like ECG pattern, such as hyperkalemia, fever, medications with sodium ion channel blocking properties, and lead placement.

**Profound Sinus Bradycardia or First Degree AV Block**

Sinus bradycardia and moderate prolongation of the PR interval (200 to 399 ms) are recognized features of athletic conditioning. Although a resting heart rate ≤ 30 bpm or a PR interval ≥ 400 ms may be normal in a well-trained athlete, it should prompt further evaluation for cardiac conduction disease.

Evaluation

Evaluation of profound sinus bradycardia or a markedly increased PR interval should include assessing the chronotropic response to mild aerobic activity, such as running on the spot or climbing stairs. Exercise testing is useful in this situation to provide an objective measure of the PR interval and heart rate response to aerobic activity. If the heart rate increases appropriately and the PR interval normalizes, and the athlete is asymptomatic, no further testing is necessary. Conversely, further evaluation should be performed if the heart rate does not increase or the PR interval does not shorten appropriately on exertion, the athlete experiences pre-syncope/syncope, or in athletes with a family history of cardiac disease or sudden death. Depending on the clinical scenario, an echocardiogram or ambulatory ECG monitor may be indicated.

**High Grade AV Block**

Mobitz type II second degree AV block and third degree (complete) AV block are abnormal findings in athletes. Complete heart block can be confused with AV dissociation without block; a situation where the junctional pacemaker is faster than the sinus node, leading to more QRS complexes than P waves. Intermittent ventricular capture by sinus P waves (resulting in an irregular ventricular response) excludes complete AV block. AV dissociation without block is the expression of autonomic mismatch between AV and sinus nodal modulation, but is not pathological. Like all other functional disturbances, a small exercise load with repeat ECG recording will show resolution of the ECG findings in AV dissociation.

Evaluation

If Mobitz II AV block or complete AV block is detected, further evaluation includes an echocardiogram, ambulatory ECG monitor, and exercise ECG test. Based on these results, laboratory testing and cardiac MRI may be considered. Referral to an electrophysiologist is essential.

**Multiple Premature Ventricular Contractions**

Multiple (≥ 2) premature ventricular contractions (PVCs) are uncommon and present in < 1% of athlete ECGs.9, 12 While multiple PVCs are usually benign in a highly trained athlete, their presence may be the hallmark of underlying heart disease.111, 112 Therefore, the finding of ≥ 2 PVCs on an ECG should prompt more extensive evaluation to exclude underlying structural heart disease.

Evaluation

The extent of evaluation for ≥ 2 PVCs is controversial and excluding pathology may be difficult. At a minimum, an ambulatory Holter monitor, echocardiogram, and exercise stress test should be performed. The availability of modern small, leadless ambulatory recorders allows for longer electrocardiographic monitoring, including during training and competition, to exclude complex ventricular arrhythmias. If the Holter and echocardiogram are normal and the PVCs suppress with exercise, no further evaluation is recommended for an asymptomatic athlete. A previous study has shown that among athletes with ≥ 2,000 PVCs per 24 hours, up to 30% were found to have underlying structural heart disease, compared to 3% and 0% in those with < 2,000 and < 100 PVCs per day, respectively.112 Therefore, in athletes with ≥ 2,000 PVCs per 24 hours or with episodes of non-sustained ventricular tachycardia, or with an increasing burden of ectopy during an incremental exercise test, additional evaluation may include contrast-enhanced cardiac MRI and more invasive electrophysiology study.113, 114 Although some studies have suggested that regression of the PVC burden with detraining indicates a good prognosis, other studies have not confirmed this.115-117 Thus, detraining as a diagnostic or therapeutic measure is not recommended.

*Considerations in High-Dynamic Athletes*

There is some evidence from symptomatic athletes that high-level endurance sport could promote or induce ARVC, even in the absence of desmosomal mutations or a family history.114, 118-120 PVCs originating from the right ventricular outflow tract conduct with a LBBB pattern and an inferior axis and are usually regarded as benign. The ECG in such patients is otherwise normal and does not reveal T wave inversion. In contrast, PVCs originating from the main body of the right ventricle typically show a LBBB pattern and superior axis (predominantly negative QRS vector in V1 and the inferior leads) and may be associated with right ventricular pathology particularly in the context of other ECG abnormalities. Therefore, a lower threshold for extensive evaluation of a single PVC may be warranted in high-dynamic athletes, especially when ≥ 25 years of age and with a LBBB morphology and superior axis.

**Atrial Tachyarrhythmias**

Sinus tachycardia is the most common atrial tachyarrhythmia but is very rarely due to intrinsic cardiac disease. Supraventricular tachycardia (SVT), atrial fibrillation, and atrial flutter are rarely seen on a resting ECG in athletes and require investigation. Atrial tachyarrhythmias are rarely life threatening but can be associated with other conditions that can lead to SCD, including LQTS, WPW, BrS, myocarditis, congenital heart disease, and the cardiomyopathies.

Evaluation

If resting sinus tachycardia > 120 bpm is seen, a repeat ECG should be considered after a period of rest as recent exercise or anxiety may be the cause. Other underlying etiologies may be sought, including fever, infection, dehydration, stimulant use, anemia, hyperthyroidism, or, rarely, underlying cardiac or pulmonary disease.

For paroxysmal SVT, a repeat ECG when not in SVT should be obtained if possible. If the Valsalva maneuver, carotid sinus massage, or the diving reflex is used to terminate the arrhythmia, a rhythm strip should be obtained which can help elucidate the mechanism of the SVT. An echocardiogram, ambulatory ECG monitor, and exercise treadmill test should be completed. Referral to an electrophysiologist may be indicated for consideration of electrophysiology study and ablation.

If atrial fibrillation or flutter is found, an echocardiogram should be completed to assess for structural heart disease and anti-coagulation considered based on standard guidelines.121 An ambulatory ECG monitor should be used to assess if the rhythm is paroxysmal or persistent and what the ventricular rate is throughout the day. A thorough family history may elucidate an underlying genetic cause. Depending on what these results show, cardiac MRI, electrophysiology study with possible ablation, and/or genetic testing may be considered.

**Ventricular Arrhythmias**

Ventricular couplets, triplets, and non-sustained ventricular tachycardia always require investigation as they can be a marker for underlying cardiac pathology or lead to sustained ventricular tachycardia which may cause SCD.

Evaluation

If ventricular arrhythmias are seen, the evaluation should include a thorough family history, an echocardiogram to evaluate for structural heart disease, cardiac MRI to assess for ARVC or other cardiomyopathies, ambulatory ECG monitor and exercise ECG test. Depending on these results, further evaluation may be needed including electrophysiology study or genetic testing.

**Considerations in Athletes ≥ 30 Years of Age**

In athletes ≥ 30 years of age, CAD is the most common cause of SCD.89, 90 In addition, older athletes may be less fit compared to 20-30 years ago, increasing the possibility of underlying CAD.122, 123 While resting ECGs have a low sensitivity for CAD, some ECG patterns may suggest underlying CAD such as TWI, pathological Q waves, ST segment depression, left or right bundle branch block, abnormal R wave progression, left anterior hemiblock, and atrial fibrillation.124-126

Evaluation

The main role of a resting ECG in older athletes is to identify those athletes who may potentially be at high risk for CAD and warrant further testing.125, 127, 128 Initial testing should include an exercise stress test, resting echocardiogram, and assessment of traditional risk factors for CAD. When indicated, this evaluation may be complemented by coronary CT angiography or a functional stress test.

**ECG Patterns Requiring Serial Evaluation**

Several common heritable cardiomyopathies may present with ECG abnormalities prior to the onset of overt heart muscle pathology.62, 63 Therefore, athletes with abnormal ECGs suggestive of cardiomyopathy and initially normal clinical evaluations should be followed with serial evaluation during and after their competitive athletic careers. Evaluations may be conducted annually or more frequently depending on individual circumstances. These athletes may be permitted to participate in competitive athletics without restriction contingent on longitudinal follow-up.

**CONCLUSION**

Accurate ECG interpretation in athletes requires adequate training and an attention to detail to distinguish physiological ECG findings from abnormal ECG findings that might indicate the presence of cardiac pathology. The international consensus standards presented on ECG interpretation and the evaluation of ECG abnormalities serve as an important foundation for improving the quality of cardiovascular care of athletes. As new scientific data become available, revision of these recommendations may be necessary to further advance the accuracy of ECG interpretation in the athletic population.

**Acknowledgements:**

The *2nd Summit on Electrocardiogram Interpretation in Athletes* was sponsored by the American Medical Society for Sports Medicine (AMSSM), the FIFA Medical Assessment and Research Center (F-MARC), and the National Collegiate Athletic Association (NCAA). Participating medical societies included the American College of Cardiology (ACC) Sports & Exercise Council, and the Section on Sports Cardiology of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR), a registered branch of the European Society of Cardiology (ESC).

**FIGURE LEGENDS**

Figure 1. International Consensus Standards for Electrocardiographic Interpretation in Athletes

Figure 2. ECG of a 29 year old male asymptomatic soccer player showing sinus bradycardia (44 bpm), early repolarization in I, II, aVF, V2-V6 (arrows), voltage criterion for LVH (S-V1 + R-V5 > 35 mm), and tall, peaked T waves (circles). These are common, training related findings in athletes and do not require more evaluation.

Figure 3. ECG from a black athlete demonstrating voltage criterion for LVH, and convex (‘domed’) ST segment elevation followed by TWI in V1-V4 (circles). This is a normal repolarization pattern in black athletes.

Figure 4. Normal and abnormal patterns of TWI. (A) Anterior TWI in V1-V3 in a 12 year old asymptomatic athlete without a family history of SCD considered a normal “juvenile” pattern. (B) TWI in V1-V4 in a 17 year old asymptomatic mixed race (Middle-Eastern/black) athlete without a family history of SCD. This is a normal repolarization pattern in black athletes. (C) Biphasic TWI in V3 in a 31 year old asymptomatic black athlete without a family history of SCD. Anterior biphasic T waves are considered normal in adolescents < 16 years old and in adults when found in a single lead, most commonly V3. (D) Abnormal TWI in V1-V6 in an adult symptomatic former soccer player with genetically confirmed ARVC and a positive family history of SCD (brother died at 26 years of age). (E) Inferolateral TWI in leads I, II, III, aVF, V2-V6 and ST segment depression in leads II, aVF, V4-V6 in a 31 year old asymptomatic professional soccer referee. These markedly abnormal findings require a comprehensive evaluation to exclude cardiomyopathy. (F) An ECG demonstrating the type 1 Brugada pattern with high take-off ST elevation ≥ 2 mm with downsloping ST segment elevation followed by a negative symmetric T wave in V1-V2.

Figure 5. Examples of physiological (A) and pathological TWI (B). Panel A demonstrates TWI in V1-V4 preceded by convex ‘domed’ ST segment elevation (green circles). This should not be confused with pathological TWI (Panel B) which demonstrates TWI in V1-V6 with absent J-point elevation and a downsloping ST segment (red circles).

Figure 6. This figure illustrates the “Teach-the-Tangent” or “Avoid-the-Tail” method for manual measurement of the QT interval. A straight line is drawn on the downslope of the T wave to the point of intersection with the isoelectric line. The U wave is not included in the measurement.

Figure 7. Brugada type 1 ECG (left) should be distinguished from early repolarization with “convex” ST segment elevation in a trained athlete (right). Vertical lines mark the J-point (STJ) and the point 80 ms after the J-point (ST80), where the amplitudes of the ST segment elevation are calculated. The ‘downsloping’ ST segment elevation in Brugada pattern is characterized by a STJ/ST80 ratio > 1. Early repolarization patterns in an athlete show an initial ‘upsloping’ ST segment elevation with STJ/ST80 ratio < 1.

**REFERENCES**

1. Harmon KG, Asif IM, Klossner D and Drezner JA. Incidence of sudden cardiac death in national collegiate athletic association athletes. *Circulation*. 2011;123:1594-1600.

2. Maron BJ, Doerer JJ, Haas TS, Tierney DM and Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. *Circulation*. 2009;119:1085-1092.

3. Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, Zigman ML, Ellenbogen R, Rao A, Ackerman MJ and Drezner JA. Incidence, Etiology, and Comparative Frequency of Sudden Cardiac Death in NCAA Athletes: A Decade in Review. *Circulation*. 2015;132:10-19.

4. Corrado D, Biffi A, Basso C, Pelliccia A and Thiene G. 12-lead ECG in the athlete: physiological versus pathological abnormalities. *Br J Sports Med*. 2009;43:669-676.

5. Corrado D, Pelliccia A, Heidbuchel H, Sharma S, Link M, Basso C, Biffi A, Buja G, Delise P, Gussac I, Anastasakis A, Borjesson M, Bjornstad HH, Carre F, Deligiannis A, Dugmore D, Fagard R, Hoogsteen J, Mellwig KP, Panhuyzen-Goedkoop N, Solberg E, Vanhees L, Drezner J, Estes NA, 3rd, Iliceto S, Maron BJ, Peidro R, Schwartz PJ, Stein R, Thiene G, Zeppilli P and McKenna WJ. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. *Eur Heart J*. 2010;31:243-259.

6. Uberoi A, Stein R, Perez MV, Freeman J, Wheeler M, Dewey F, Peidro R, Hadley D, Drezner J, Sharma S, Pelliccia A, Corrado D, Niebauer J, Estes NA, 3rd, Ashley E and Froelicher V. Interpretation of the electrocardiogram of young athletes. *Circulation*. 2011;124:746-757.

7. Williams ES, Owens DS, Drezner JA and Prutkin JM. Electrocardiogram interpretation in the athlete. *Herzschrittmacherther Elektrophysiol*. 2012;23:65-71.

8. Drezner J. Standardised criteria for ECG interpretation in athletes: a practical tool. *Br J Sports Med*. 2012;46: i6-i8.

9. Marek J, Bufalino V, Davis J, Marek K, Gami A, Stephan W and Zimmerman F. Feasibility and findings of large-scale electrocardiographic screening in young adults: data from 32,561 subjects. *Heart Rhythm*. 2011;8:1555-1559.

10. Drezner JA, Ackerman MJ, Anderson J, Ashley E, Asplund CA, Baggish AL, Borjesson M, Cannon BC, Corrado D, DiFiori JP, Fischbach P, Froelicher V, Harmon KG, Heidbuchel H, Marek J, Owens DS, Paul S, Pelliccia A, Prutkin JM, Salerno JC, Schmied CM, Sharma S, Stein R, Vetter VL and Wilson MG. Electrocardiographic interpretation in athletes: the 'Seattle criteria'. *Br J Sports Med*. 2013;47:122-124.

11. Corrado D, Pelliccia A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M, Panhuyzen-Goedkoop N, Deligiannis A, Solberg E, Dugmore D, Mellwig KP, Assanelli D, Delise P, van-Buuren F, Anastasakis A, Heidbuchel H, Hoffmann E, Fagard R, Priori SG, Basso C, Arbustini E, Blomstrom-Lundqvist C, McKenna WJ and Thiene G. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. *Eur Heart J*. 2005;26:516-524.

12. Pelliccia A, Culasso F, Di Paolo FM, Accettura D, Cantore R, Castagna W, Ciacciarelli A, Costini G, Cuffari B, Drago E, Federici V, Gribaudo CG, Iacovelli G, Landolfi L, Menichetti G, Atzeni UO, Parisi A, Pizzi AR, Rosa M, Santelli F, Santilio F, Vagnini A, Casasco M and Di Luigi L. Prevalence of abnormal electrocardiograms in a large, unselected population undergoing pre-participation cardiovascular screening. *Eur Heart J*. 2007;28:2006-2010.

13. Drezner JA, Fischbach P, Froelicher V, Marek J, Pelliccia A, Prutkin JM, Schmied CM, Sharma S, Wilson MG, Ackerman MJ, Anderson J, Ashley E, Asplund CA, Baggish AL, Borjesson M, Cannon BC, Corrado D, DiFiori JP, Harmon KG, Heidbuchel H, Owens DS, Paul S, Salerno JC, Stein R and Vetter VL. Normal electrocardiographic findings: recognising physiological adaptations in athletes. *Br J Sports Med*. 2013;47:125-136.

14. Drezner JA, Ashley E, Baggish AL, Borjesson M, Corrado D, Owens DS, Patel A, Pelliccia A, Vetter VL, Ackerman MJ, Anderson J, Asplund CA, Cannon BC, DiFiori J, Fischbach P, Froelicher V, Harmon KG, Heidbuchel H, Marek J, Paul S, Prutkin JM, Salerno JC, Schmied CM, Sharma S, Stein R and Wilson M. Abnormal electrocardiographic findings in athletes: recognising changes suggestive of cardiomyopathy. *Br J Sports Med*. 2013;47:137-152.

15. Drezner JA, Ackerman MJ, Cannon BC, Corrado D, Heidbuchel H, Prutkin JM, Salerno JC, Anderson J, Ashley E, Asplund CA, Baggish AL, Borjesson M, DiFiori JP, Fischbach P, Froelicher V, Harmon KG, Marek J, Owens DS, Paul S, Pelliccia A, Schmied CM, Sharma S, Stein R, Vetter VL and Wilson MG. Abnormal electrocardiographic findings in athletes: recognising changes suggestive of primary electrical disease. *Br J Sports Med*. 2013;47:153-167.

16. Brosnan M, La Gerche A, Kumar S, Lo W, Kalman J and Prior D. Modest agreement in ECG interpretation limits the application of ECG screening in young athletes. *Heart Rhythm*. 2015;12:130-136.

17. Magee C, Kazman J, Haigney M, Oriscello R, DeZee KJ, Deuster P, Depenbrock P and O'Connor FG. Reliability and validity of clinician ECG interpretation for athletes. *Ann Noninvasive Electrocardiol*. 2014;19:319-329.

18. Hill AC, Miyake CY, Grady S and Dubin AM. Accuracy of Interpretation of Preparticipation Screening Electrocardiograms. *J Pediatr*. 2011;159:783-788.

19. Drezner JA, Asif IM, Owens DS, Prutkin JM, Salerno JC, Fean R, Rao AL, Stout K and Harmon KG. Accuracy of ECG interpretation in competitive athletes: the impact of using standised ECG criteria. *Br J Sports Med*. 2012;46:335-340.

20. Exeter DJ, Elley CR, Fulcher ML, Lee AC, Drezner JA and Asif IM. Standardised criteria improve accuracy of ECG interpretation in competitive athletes: a randomised controlled trial. *Br J Sports Med*. 2014;48:1167-1171.

21. Ryan MP, Cleland JG, French JA, Joshi J, Choudhury L, Chojnowska L, Michalak E, al-Mahdawi S, Nihoyannopoulos P and Oakley CM. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. *Am J Cardiol*. 1995;76:689-694.

22. Papadakis M, Basavarajaiah S, Rawlins J, Edwards C, Makan J, Firoozi S, Carby L and Sharma S. Prevalence and significance of T-wave inversions in predominantly Caucasian adolescent athletes. *Eur Heart J*. 2009;30:1728-1735.

23. Pelliccia A, Maron BJ, Culasso F, Di Paolo FM, Spataro A, Biffi A, Caselli G and Piovano P. Clinical significance of abnormal electrocardiographic patterns in trained athletes. *Circulation*. 2000;102:278-284.

24. Sohaib SM, Payne JR, Shukla R, World M, Pennell DJ and Montgomery HE. Electrocardiographic (ECG) criteria for determining left ventricular mass in young healthy men; data from the LARGE Heart study. *J Cardiovasc Magn Reson*. 2009;11:2.

25. Sathanandam S, Zimmerman F, Davis J and Marek J. Abstract 2484: ECG Screening Criteria for LVH Does Not Correlate With Diagnosis of Hypertrophic Cardiomyopathy. *Circulation*. 2009:S647.

26. Weiner RB, Hutter AM, Wang F, Kim JH, Wood MJ, Wang TJ, Picard MH and Baggish AL. Performance of the 2010 European Society of Cardiology criteria for ECG interpretation in the athlete. *Heart*. 2011;97:1573-1577.

27. Calore C, Melacini P, Pelliccia A, Cianfrocca C, Schiavon M, Di Paolo FM, Bovolato F, Quattrini FM, Basso C, Thiene G, Iliceto S and Corrado D. Prevalence and clinical meaning of isolated increase of QRS voltages in hypertrophic cardiomyopathy versus athlete's heart: relevance to athletic screening. *Int J Cardiol*. 2013;168:4494-4497.

28. Lakdawala NK, Thune JJ, Maron BJ, Cirino AL, Havndrup O, Bundgaard H, Christiansen M, Carlsen CM, Dorval JF, Kwong RY, Colan SD, Kober LV and Ho CY. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. *Am J Cardiol*. 2011;108:1606-1613.

29. Sheikh N, Papadakis M, Ghani S, Zaidi A, Gati S, Adami PE, Carre F, Schnell F, Wilson M, Avila P, McKenna W and Sharma S. Comparison of electrocardiographic criteria for the detection of cardiac abnormalities in elite black and white athletes. *Circulation*. 2014;129:1637-1649.

30. Papadakis M, Carre F, Kervio G, Rawlins J, Panoulas VF, Chandra N, Basavarajaiah S, Carby L, Fonseca T and Sharma S. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin. *Eur Heart J*. 2011;32:2304-2313.

31. Zaidi A, Ghani S, Sheikh N, Gati S, Bastiaenen R, Madden B, Papadakis M, Raju H, Reed M, Sharma R, Behr ER and Sharma S. Clinical significance of electrocardiographic right ventricular hypertrophy in athletes: comparison with arrhythmogenic right ventricular cardiomyopathy and pulmonary hypertension. *Eur Heart J*. 2013;34:3649-3656.

32. Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA, Reunanen A and Huikuri HV. Long-term outcome associated with early repolarization on electrocardiography. *N Engl J Med*. 2009;361:2529-2537.

33. Haissaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, Pasquie JL, Nogami A, Babuty D, Yli-Mayry S, De Chillou C, Scanu P, Mabo P, Matsuo S, Probst V, Le Scouarnec S, Defaye P, Schlaepfer J, Rostock T, Lacroix D, Lamaison D, Lavergne T, Aizawa Y, Englund A, Anselme F, O'Neill M, Hocini M, Lim KT, Knecht S, Veenhuyzen GD, Bordachar P, Chauvin M, Jais P, Coureau G, Chene G, Klein GJ and Clementy J. Sudden cardiac arrest associated with early repolarization. *N Engl J Med*. 2008;358:2016-2023.

34. Macfarlane PW, Antzelevitch C, Haissaguerre M, Huikuri HV, Potse M, Rosso R, Sacher F, Tikkanen JT, Wellens H and Yan GX. The Early Repolarization Pattern: A Consensus Paper. *J Am Coll Cardiol*. 2015;66:470-477.

35. Tikkanen JT, Junttila MJ, Anttonen O, Aro AL, Luttinen S, Kerola T, Sager SJ, Rissanen HA, Myerburg RJ, Reunanen A and Huikuri HV. Early repolarization: electrocardiographic phenotypes associated with favorable long-term outcome. *Circulation*. 2011;123:2666-2673.

36. Uberoi A, Jain NA, Perez M, Weinkopff A, Ashley E, Hadley D, Turakhia MP and Froelicher V. Early repolarization in an ambulatory clinical population. *Circulation*. 2011;124:2208-2214.

37. Junttila MJ, Sager SJ, Freiser M, McGonagle S, Castellanos A and Myerburg RJ. Inferolateral early repolarization in athletes. *J Interv Card Electrophysiol*. 2011;31:33-38.

38. Noseworthy PA, Weiner R, Kim J, Keelara V, Wang F, Berkstresser B, Wood MJ, Wang TJ, Picard MH, Hutter AM, Jr., Newton-Cheh C and Baggish AL. Early repolarization pattern in competitive athletes: clinical correlates and the effects of exercise training. *Circ Arrhythm Electrophysiol*. 2011;4:432-440.

39. Noseworthy PA, Tikkanen JT, Porthan K, Oikarinen L, Pietila A, Harald K, Peloso GM, Merchant FM, Jula A, Vaananen H, Hwang SJ, O'Donnell CJ, Salomaa V, Newton-Cheh C and Huikuri HV. The early repolarization pattern in the general population: clinical correlates and heritability. *J Am Coll Cardiol*. 2011;57:2284-2289.

40. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman MM, Zeltser D, Halkin A, Steinvil A, Heller K, Glikson M, Katz A and Viskin S. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. *J Am Coll Cardiol*. 2008;52:1231-1238.

41. Quattrini FM, Pelliccia A, Assorgi R, DiPaolo FM, Squeo MR, Culasso F, Castelli V, Link MS and Maron BJ. Benign clinical significance of J-wave pattern (early repolarization) in highly trained athletes. *Heart Rhythm*. 2014;11:1974-1982.

42. Sheikh N, Papadakis M, Carre F, Kervio G, Panoulas VF, Ghani S, Zaidi A, Gati S, Rawlins J, Wilson MG and Sharma S. Cardiac adaptation to exercise in adolescent athletes of African ethnicity: an emergent elite athletic population. *Br J Sports Med*. 2013;47:585-592.

43. Di Paolo FM, Schmied C, Zerguini YA, Junge A, Quattrini F, Culasso F, Dvorak J and Pelliccia A. The athlete's heart in adolescent Africans: an electrocardiographic and echocardiographic study. *J Am Coll Cardiol*. 2012;59:1029-1036.

44. Rawlins J, Carre F, Kervio G, Papadakis M, Chandra N, Edwards C, Whyte GP and Sharma S. Ethnic differences in physiological cardiac adaptation to intense physical exercise in highly trained female athletes. *Circulation*. 2010;121:1078-1085.

45. Migliore F, Zorzi A, Michieli P, Perazzolo Marra M, Siciliano M, Rigato I, Bauce B, Basso C, Toazza D, Schiavon M, Iliceto S, Thiene G and Corrado D. Prevalence of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave inversion at preparticipation screening. *Circulation*. 2012;125:529-538.

46. Calo L, Sperandii F, Martino A, Guerra E, Cavarretta E, Quaranta F, Ruvo E, Sciarra L, Parisi A, Nigro A, Spataro A and Pigozzi F. Echocardiographic findings in 2261 peri-pubertal athletes with or without inverted T waves at electrocardiogram. *Heart*. 2015;101:193-200.

47. Sharma S, Whyte G, Elliott P, Padula M, Kaushal R, Mahon N and McKenna WJ. Electrocardiographic changes in 1000 highly trained junior elite athletes. *Br J Sports Med*. 1999;33:319-324.

48. Stein R, Medeiros CM, Rosito GA, Zimerman LI and Ribeiro JP. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. *J Am Coll Cardiol*. 2002;39:1033-1038.

49. Northcote RJ, Canning GP and Ballantyne D. Electrocardiographic findings in male veteran endurance athletes. *Br Heart J*. 1989;61:155-160.

50. Meytes I, Kaplinsky E, Yahini JH, Hanne-Paparo N and Neufeld HN. Wenckebach A-V block: a frequent feature following heavy physical training. *Am Heart J*. 1975;90:426-430.

51. Gati S, Sheikh N, Ghani S, Zaidi A, Wilson M, Raju H, Cox A, Reed M, Papadakis M and Sharma S. Should axis deviation or atrial enlargement be categorised as abnormal in young athletes? The athlete's electrocardiogram: time for re-appraisal of markers of pathology. *Eur Heart J*. 2013;34:3641-3648.

52. Fudge J, Harmon KG, Owens DS, Prutkin JM, Salerno JC, Asif IM, Haruta A, Pelto H, Rao AL, Toresdahl BG and Drezner JA. Cardiovascular screening in adolescents and young adults: a prospective study comparing the Pre-participation Physical Evaluation Monograph 4th Edition and ECG. *Br J Sports Med*. 2014;48:1172-1178.

53. Magalski A, McCoy M, Zabel M, Magee LM, Goeke J, Main ML, Bunten L, Reid KJ and Ramza BM. Cardiovascular screening with electrocardiography and echocardiography in collegiate athletes. *Am J Med*. 2011;124:511-518.

54. Baggish AL, Hutter AM, Jr., Wang F, Yared K, Weiner RB, Kupperman E, Picard MH and Wood MJ. Cardiovascular screening in college athletes with and without electrocardiography: A cross-sectional study. *Ann Intern Med*. 2010;152:269-275.

55. Kim JH, Noseworthy PA, McCarty D, Yared K, Weiner R, Wang F, Wood MJ, Hutter AM, Picard MH and Baggish AL. Significance of electrocardiographic right bundle branch block in trained athletes. *Am J Cardiol*. 2011;107:1083-1089.

56. Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ and Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. *Am J Cardiol*. 2012;110:1027-1032.

57. Chen X, Zhao T, Lu M, Yin G, Xiangli W, Jiang S, Prasad S and Zhao S. The relationship between electrocardiographic changes and CMR features in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. *Int J Cardiovasc Imaging*. 2014;30 Suppl 1:55-63.

58. Sheikh N, Papadakis M, Schnell F, Panoulas V, Malhotra A, Wilson M, Carre F and Sharma S. Clinical Profile of Athletes With Hypertrophic Cardiomyopathy. *Circ Cardiovasc Imaging*. 2015;8:e003454.

59. Bent RE, Wheeler MT, Hadley D, Knowles JW, Pavlovic A, Finocchiaro G, Haddad F, Salisbury H, Race S, Shmargad Y, Matheson GO, Kumar N, Saini D, Froelicher V, Ashley E and Perez MV. Systematic Comparison of Digital Electrocardiograms From Healthy Athletes and Patients With Hypertrophic Cardiomyopathy. *J Am Coll Cardiol*. 2015;65:2462-2463.

60. Nasir K, Bomma C, Tandri H, Roguin A, Dalal D, Prakasa K, Tichnell C, James C, Spevak PJ, Marcus F and Calkins H. Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. *Circulation*. 2004;110:1527-1534.

61. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T and Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. *Circulation*. 2010;121:1533-1541.

62. Pelliccia A, Di Paolo FM, Quattrini FM, Basso C, Culasso F, Popoli G, De Luca R, Spataro A, Biffi A, Thiene G and Maron BJ. Outcomes in athletes with marked ECG repolarization abnormalities. *N Engl J Med*. 2008;358:152-161.

63. Schnell F, Riding N, O'Hanlon R, Axel Lentz P, Donal E, Kervio G, Matelot D, Leurent G, Doutreleau S, Chevalier L, Guerard S, Wilson MG and Carre F. Recognition and significance of pathological T-wave inversions in athletes. *Circulation*. 2015;131:165-173.

64. Chandra N, Bastiaenen R, Papadakis M, Panoulas VF, Ghani S, Duschl J, Foldes D, Raju H, Osborne R and Sharma S. Prevalence of electrocardiographic anomalies in young individuals: relevance to a nationwide cardiac screening program. *J Am Coll Cardiol*. 2014;63:2028-2034.

65. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C and Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35:2733-2779.

66. Calore C, Zorzi A, Sheikh N, Nese A, Facci M, Malhotra A, Zaidi A, Schiavon M, Pelliccia A, Sharma S and Corrado D. Electrocardiographic anterior T-wave inversion in athletes of different ethnicities: differential diagnosis between athlete's heart and cardiomyopathy. *Eur Heart J*. 2015 Nov 17. [Epub ahead of print]

67. Brosnan M, La Gerche A, Kalman J, Lo W, Fallon K, MacIsaac A and Prior DL. Comparison of frequency of significant electrocardiographic abnormalities in endurance versus nonendurance athletes. *Am J Cardiol*. 2014;113:1567-1573.

68. Malhotra A, Walker M, Dhutia H, Richards T, Narain R, Merghani A, Millar L, Ah-Fong J, Papadakis M and Sharma S. ECG interpretation in the athlete: A comparison of ethnic groups when three different criteria are applied. *Eur J Prev Cardiol*. 2015;22:s84-s85.

69. Riding NR, Salah O, Sharma S, Carre F, George KP, Farooq A, Hamilton B, Chalabi H, Whyte GP and Wilson MG. ECG and morphologic adaptations in Arabic athletes: are the European Society of Cardiology's recommendations for the interpretation of the 12-lead ECG appropriate for this ethnicity? *Br J Sports Med*. 2014;48:1138-1143.

70. Maron BJ, Wolfson JK, Ciro E and Spirito P. Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 1983;51:189-194.

71. Haghjoo M, Mohammadzadeh S, Taherpour M, Faghfurian B, Fazelifar AF, Alizadeh A, Rad MA and Sadr-Ameli MA. ST-segment depression as a risk factor in hypertrophic cardiomyopathy. *Europace*. 2009;11:643-649.

72. MacAlpin RN. Clinical significance of QS complexes in V1 and V2 without other electrocardiographic abnormality. *Ann Noninvasive Electrocardiol*. 2004;9:39-47.

73. Bent RE, Wheeler MT, Hadley D, Froelicher V, Ashley E and Perez MV. Computerized Q wave dimensions in athletes and hypertrophic cardiomyopathy patients. *J Electrocardiol*. 2015;48:362-367.

74. Riding NR, Sheikh N, Adamuz C, Watt V, Farooq A, Whyte GP, George KP, Drezner JA, Sharma S and Wilson MG. Comparison of three current sets of electrocardiographic interpretation criteria for use in screening athletes. *Heart*. 2014;101:384-390.

75. Kim JH and Baggish AL. Electrocardiographic right and left bundle branch block patterns in athletes: prevalence, pathology, and clinical significance. *J Electrocardiol*. 2015;48:380-384.

76. Le VV, Wheeler MT, Mandic S, Dewey F, Fonda H, Perez M, Sungar G, Garza D, Ashley EA, Matheson G and Froelicher V. Addition of the electrocardiogram to the preparticipation examination of college athletes. *Clin J Sport Med*. 2010;20:98-105.

77. Aro AL, Anttonen O, Tikkanen JT, Junttila MJ, Kerola T, Rissanen HA, Reunanen A and Huikuri HV. Intraventricular conduction delay in a standard 12-lead electrocardiogram as a predictor of mortality in the general population. *Circ Arrhythm Electrophysiol*. 2011;4:704-710.

78. Desai AD, Yaw TS, Yamazaki T, Kaykha A, Chun S and Froelicher VF. Prognostic Significance of Quantitative QRS Duration. *Am J Med*. 2006;119:600-606.

79. Dunn T, Abdelfattah R, Aggarwal S, Pickham D, Hadley D and Froelicher V. Are the QRS duration and ST depression cut-points from the Seattle criteria too conservative? *J Electrocardiol*. 2015;48:395-398.

80. Xiao HB, Brecker SJ and Gibson DG. Relative effects of left ventricular mass and conduction disturbance on activation in patients with pathological left ventricular hypertrophy. *Br Heart J*. 1994;71:548-553.

81. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, Rautaharju PM, van Herpen G, Wagner GS and Wellens H. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *Circulation*. 2009;119:e235-e240.

82. Drezner JA, Prutkin JM, Harmon KG, O'Kane JW, Pelto HF, Rao AL, Hassebrock JD, Petek BJ, Teteak C, Timonen M, Zigman M and Owens DS. Cardiovascular screening in college athletes. *J Am Coll Cardiol*. 2015;65:2353-2355.

83. Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S and Tanel RE. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). *Heart Rhythm*. 2012;9:1006-1024.

84. Daubert C, Ollitrault J, Descaves C, Mabo P, Ritter P and Gouffault J. Failure of the exercise test to predict the anterograde refractory period of the accessory pathway in Wolff Parkinson White syndrome. *Pacing Clin Electrophysiol*. 1988;11:1130-1138.

85. Klein GJ and Gulamhusein SS. Intermittent preexcitation in the Wolff-Parkinson-White syndrome. *Am J Cardiol*. 1983;52:292-296.

86. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM and Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. *N Engl J Med*. 1979;301:1080-1085.

87. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini F, Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P and Spazzolini C. Prevalence of the congenital long-QT syndrome. *Circulation*. 2009;120:1761-1767.

88. Tester DJ and Ackerman MJ. Cardiomyopathic and channelopathic causes of sudden unexplained death in infants and children. *Annu Rev Med*. 2009;60:69-84.

89. Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM, Avedissian L, Pearse LA, Potter RN, Tremaine L, Gentlesk PJ, Huffer L, Reich SS and Stevenson WG. Sudden death in young adults an autopsy-based series of a population undergoing active surveillance. *J Am Coll Cardiol*. 2011;58:1254-1261.

90. Meyer L, Stubbs B, Fahrenbruch C, Maeda C, Harmon K, Eisenberg M and Drezner J. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. *Circulation*. 2012;126:1363-1372.

91. Behr E, Wood DA, Wright M, Syrris P, Sheppard MN, Casey A, Davies MJ and McKenna W. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. *Lancet*. 2003;362:1457-1459.

92. Tester DJ, Spoon DB, Valdivia HH, Makielski JC and Ackerman MJ. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. *Mayo Clin Proc*. 2004;79:1380-1384.

93. Tan HL, Hofman N, van Langen IM, van der Wal AC and Wilde AA. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. *Circulation*. 2005;112:207-213.

94. Finocchiaro G, Papadakis M, Robertus JL, Dhutia H, Steriotis AK, Tome M, Mellor G, Merghani A, Malhotra A, Behr E, Sharma S and Sheppard MN. Etiology of Sudden Death in Sports: Insights From a United Kingdom Regional Registry. *J Am Coll Cardiol*. 2016;67:2108-2115.

95. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FF, Centurion OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM and Zeltser D. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. *Heart Rhythm*. 2005;2:569-574.

96. Postema PG, De Jong JS, Van der Bilt IA and Wilde AA. Accurate electrocardiographic assessment of the QT interval: teach the tangent. *Heart Rhythm*. 2008;5:1015-1018.

97. Bazett HC. An analysis of the time-relations of electrocardiograms. *Heart*. 1920:353-370.

98. Malfatto G, Beria G, Sala S, Bonazzi O and Schwartz PJ. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. *J Am Coll Cardiol*. 1994;23:296-301.

99. Ackerman MJ, Zipes DP, Kovacs RJ and Maron BJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. *J Am Coll Cardiol*. 2015;66:2424-2428.

100. Dhutia H, Malhotra A, Parpia S, Gabus V, Finocchiaro G, Mellor G, Merghani A, Millar L, Narain R, Sheikh N, Behr ER, Papadakis M and Sharma S. The prevalence and significance of a short QT interval in 18 825 low-risk individuals including athletes. *Br J Sports Med*. 2016;50:124-129.

101. Basavarajaiah S, Wilson M, Whyte G, Shah A, Behr E and Sharma S. Prevalence and significance of an isolated long QT interval in elite athletes. *Eur Heart J*. 2007;28:2944-2949.

102. Goldenberg I, Moss AJ, Peterson DR, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Napolitano C, Priori SG, Qi M, Schwartz PJ, Towbin JA, Vincent GM and Zhang L. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. *Circulation*. 2008;117:2184-2191.

103. Gollob MH, Redpath CJ and Roberts JD. The short QT syndrome: proposed diagnostic criteria. *J Am Coll Cardiol*. 2011;57:802-812.

104. Schwartz PJ, Moss AJ, Vincent GM and Crampton RS. Diagnostic criteria for the long QT syndrome. An update. *Circulation*. 1993;88:782-784.

105. Schwartz PJ and Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. *Circulation*. 2011;124:2181-2184.

106. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C and Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm*. 2011;8:1308-1339.

107. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG and Towbin JA. Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation*. 2002;106:2514-2519.

108. Bayes de Luna A, Brugada J, Baranchuk A, Borggrefe M, Breithardt G, Goldwasser D, Lambiase P, Riera AP, Garcia-Niebla J, Pastore C, Oreto G, McKenna W, Zareba W, Brugada R and Brugada P. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. *J Electrocardiol*. 2012;45:433-442.

109. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G and Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm*. 2013;10:1932-1963.

110. Zorzi A, Leoni L, Di Paolo FM, Rigato I, Migliore F, Bauce B, Pelliccia A and Corrado D. Differential diagnosis between early repolarization of athlete's heart and coved-type Brugada electrocardiogram. *Am J Cardiol*. 2015;115:529-532.

111. Verdile L, Maron BJ, Pelliccia A, Spataro A, Santini M and Biffi A. Clinical significance of exercise-induced ventricular tachyarrhythmias in trained athletes without cardiovascular abnormalities. *Heart Rhythm*. 2015;12:78-85.

112. Biffi A, Pelliccia A, Verdile L, Fernando F, Spataro A, Caselli S, Santini M and Maron BJ. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. *J Am Coll Cardiol*. 2002;40:446-452.

113. Corrado D, Basso C, Leoni L, Tokajuk B, Turrini P, Bauce B, Migliore F, Pavei A, Tarantini G, Napodano M, Ramondo A, Buja G, Iliceto S and Thiene G. Three-dimensional electroanatomical voltage mapping and histologic evaluation of myocardial substrate in right ventricular outflow tract tachycardia. *J Am Coll Cardiol*. 2008;51:731-739.

114. Heidbuchel H, Hoogsteen J, Fagard R, Vanhees L, Ector H, Willems R and Van Lierde J. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. *Eur Heart J*. 2003;24:1473-1480.

115. Biffi A, Maron BJ, Verdile L, Fernando F, Spataro A, Marcello G, Ciardo R, Ammirati F, Colivicchi F and Pelliccia A. Impact of physical deconditioning on ventricular tachyarrhythmias in trained athletes. *J Am Coll Cardiol*. 2004;44:1053-1058.

116. Delise P, Lanari E, Sitta N, Centa M, Allocca G and Biffi A. Influence of training on the number and complexity of frequent VPBs in healthy athletes. *J Cardiovasc Med (Hagerstown)*. 2011;12:157-161.

117. Delise P, Sitta N, Lanari E, Berton G, Centa M, Allocca G, Cati A and Biffi A. Long-term effect of continuing sports activity in competitive athletes with frequent ventricular premature complexes and apparently normal heart. *Am J Cardiol*. 2013;112:1396-402.

118. La Gerche A, Robberecht C, Kuiperi C, Nuyens D, Willems R, de Ravel T, Matthijs G and Heidbuchel H. Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventricular origin. *Heart*. 2010;96:1268-1274.

119. Sawant AC, Bhonsale A, te Riele AS, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ, Judge DP, Calkins H and James CA. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. *J Am Heart Assoc*. 2014;3:e001471.

120. Heidbuchel H, Prior DL and Gerche AL. Ventricular arrhythmias associated with long-term endurance sports: what is the evidence? *Br J Sports Med*. 2012;46 Suppl 1:i44-i50.

121. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Le Heuzey JY, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL and Wann S. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;61:1935-1944.

122. Aagaard P, Sahlen A and Braunschweig F. Performance trends and cardiac biomarkers in a 30-km cross-country race, 1993-2007. *Med Sci Sports Exerc*. 2012;44:894-899.

123. Sahlen A, Gustafsson TP, Svensson JE, Marklund T, Winter R, Linde C and Braunschweig F. Predisposing factors and consequences of elevated biomarker levels in long-distance runners aged >or=55 years. *Am J Cardiol*. 2009;104:1434-1440.

124. Rose G, Baxter PJ, Reid DD and McCartney P. Prevalence and prognosis of electrocardiographic findings in middle-aged men. *Br Heart J*. 1978;40:636-643.

125. Chou R, Arora B, Dana T, Fu R, Walker M and Humphrey L. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2011;155:375-385.

126. Daviglus ML, Liao Y, Greenland P, Dyer AR, Liu K, Xie X, Huang CF, Prineas RJ and Stamler J. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. *JAMA*. 1999;281:530-536.

127. Borjesson M, Urhausen A, Kouidi E, Dugmore D, Sharma S, Halle M, Heidbuchel H, Bjornstad HH, Gielen S, Mezzani A, Corrado D, Pelliccia A and Vanhees L. Cardiovascular evaluation of middle-aged/ senior individuals engaged in leisure-time sport activities: position stand from the sections of exercise physiology and sports cardiology of the European Association of Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil*. 2011;18:446-458.

128. Maron BJ, Araujo CG, Thompson PD, Fletcher GF, de Luna AB, Fleg JL, Pelliccia A, Balady GJ, Furlanello F, Van Camp SP, Elosua R, Chaitman BR and Bazzarre TL. Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes: an advisory for healthcare professionals from the working groups of the World Heart Federation, the International Federation of Sports Medicine, and the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention. *Circulation*. 2001;103:327-334.